Tat-beclin 1 (Tat-BECN1)

Catalog No.S8595 Batch:S859502

Print

Technical Data

Formula

C164H251N57O45
Molecular Weight 3741.1 CAS No. 1423821-88-8
Solubility (25°C)* In vitro Water 100 mg/mL (26.73 mM)
 
 
In vivo (Add solvents to the product individually and in order)
Clear solution
5% H2O 40% PEG 300 5% Tween 80 ddH2O
5.0mg/ml Taking the 1 mL working solution as an example, add 50 μL of 100 mg/ml clarified H2O stock solution to 400 μL of PEG 300, mix evenly to clarify; add 50 μL of Tween 80 to the above system, mix evenly to clarify; Then continue to add 500 μL ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results. 
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description Tat-beclin 1 (Tat-BECN1), a peptide known to stimulate autophagy through mobilization of endogenous Beclin 1, induces autophagy in vitro and in vivo and improves clinical outcomes.
Targets
Beclin 1 [1]
In vitro Tat-beclin 1 is a cell-permeable peptide that induces autophagy. Treatment with Tat-beclin 1, but not Tat-scrambled, results in a dose-dependent decrease in amounts of p62, a selective autophagy substrate, and a dose-dependent conversion of the non-lipidated form of LC3, LC3-I, to the lipidated, autophagosome-associated form of LC3, LC3-II, in multiple cell lines and primary murine embryonic fibroblasts (MEFs). Tat-beclin 1 markedly inhibits HIV-1 replication in primary human monocyte-derived macrophages[1].
In vivo Tat-beclin 1 can induce autophagy in peripheral tissues in adult mice as well as in the central nervous system of neonatal mice. Daily Tat-beclin 1 peptide treatment is well-tolerated in both neonatal and adult mice. Tat-beclin 1 peptide improves the clinical outcome of mice with CNS WNV(West Nile virus) infection[1].

Protocol (from reference)

Cell Assay:

[1]
  • Cell lines

    human MDMs

  • Concentrations

    0.5–5 μM

  • Incubation Time

    24 h

  • Method

    For treatment of primary human MDMs, cells are washed with PBS and pre-treated with peptides (0.5-5 μM, 24 h) in 500 μl macrophage-SFM (serum-free media) before infection with HIV-1.
Animal Study:

[1]
  • Animal Models

    C57BL/6J mice

  • Dosages

    15 mg/kg

  • Administration

    i.p.

Selleck's Tat-beclin 1 (Tat-BECN1) has been cited by 10 publications

Neuronal autosis is Na+/K+-ATPase alpha 3-dependent and involved in hypoxic-ischemic neuronal death [ Cell Death Dis, 2024, 15(5):363] PubMed: 38796484
Chronic hypoxia stabilizes 3βHSD1 via autophagy suppression [ Cell Rep, 2024, 43(1):113575] PubMed: 38181788
Small cytosolic double-stranded DNA represses cyclic GMP-AMP synthase activation and induces autophagy [ Cell Rep, 2023, 42(8):112852] PubMed: 37481718
ASPP2 promotes cell apoptosis in cervical cancer through inhibiting autophagy [ Exp Ther Med, 2022, 24(6):726] PubMed: 36340606
Autophagy induction during stem cell activation plays a key role in salivary gland self-renewal [ Autophagy, 2021, 1-16] PubMed: 34009100
Moderately Inducing Autophagy Reduces Tertiary Brain Injury after Perinatal Hypoxia-Ischemia [ Cells, 2021, 10(4)898] PubMed: 33919804
Sirt7 protects chondrocytes degeneration in osteoarthritis via autophagy activation [ Eur Rev Med Pharmacol Sci, 2020, 24(18):9246-9255] PubMed: 33015765
Impaired Vps34 complex activity-mediated autophagy inhibition contributes to endothelial progenitor cells damage in the ischemic conditions. [ Biochem Biophys Res Commun, 2020, 524(3):629-635] PubMed: 32029275
Glycolytic Enzyme PKM2 Mediates Autophagic Activation to Promote Cell Survival in NPM1-Mutated Leukemia. [ Int J Biol Sci, 2019, 15(4):882-894] PubMed: 30906218
Autophagy facilitates the release of immunogenic signals following chemotherapy in 3D models of mesothelioma. [ Mol Carcinog, 2019, 10.1002/mc.23050] PubMed: 31215708

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.